LB-005 Hemera 1 carboxyhemoglobin oxygendelivery for revascularization in acute stroke: a prospective, randomized phase 1 clinical trial

ConclusionNo significant safety concerns were identified for the adjunctive use of PP-007in patients undergoing MT (ClinicalTrials.gov NCT04677777).DisclosuresI. Linfante: 2; C; Penumbra, Stryker, Q’Appel, Cerenovus. 3; C; Penumbra, Stryker, Q’Appel, Cerenovus. 4; C; Prolong Pharmaceuticals, InNeuroCo,Three Rivers, InNeuroFine, Deinde. W. Clark: None. D. Houssen: None. R. Hanel: None. R. Reshi: None. G. Dabus: 4; C; three rivers, InNeuroCo, synchron. R. Jubin: 5; C; Prolong Pharmaceuticals. T. Nguyen: None. J. Grotta: None. R. Wicks: None. M. Pervez: None. M. Cipolla: None. D. Liebeskind: None. R. Nogueira: None.

Source: Journal of NeuroInterventional Surgery - August 3, 2023 Category: Neurosurgery Authors: Linfante, I., Clark, W., Houssen, D., Hanel, R., Reshi, R., Dabus, G., Jubin, R., Nguyen, T., Grotta, J., Wicks, R., Pervez, M., Cipolla, M., Liebeskind, D., Nogueira, R. Tags: SNIS 20th annual meeting late-breaking oral abstracts Source Type: research